Jeonjin BioPharm Signs Agreement with UK Moredun Scientific for "Registration and Sales of BVDV Reducer"

[Asia Economy Reporter Hyunseok Yoo] Jeonjin Biofarm announced on the 10th that it has signed a commercialization-related contract with the UK’s Moredun Scientific to accelerate the commercialization of a damage reduction agent that reduces damage caused by sea lice (Sea Lice), parasites that infest salmon.

As the main entity of this project, Jeonjin Biofarm will oversee related experiments and registrations for product commercialization and provide natural materials. Through this, it has signed an experimental contract for sales and registration with Moredun Scientific, a leading UK research institute specializing in animal health, aquaculture, and biopharmaceutical safety testing, to conduct commercialization experiments registering the natural materials as Feed Material.

Additionally, the company is promoting product registration of sea lice damage reduction agents containing effective materials against sea lice in the EU with JW Nutrition Ltd in the UK, while also building marketing strategies for sales.

So far, Jeonjin Biofarm has secured active substances from a natural materials library in collaboration with the University of Stirling in the UK. It also conducted in vivo efficacy tests of natural materials by directly infecting salmon with sea lice at the Center for Aquaculture Technologies Canada (CATC) and achieved successful results. Alongside this, toxicity tests were performed at GLP-certified research institutions domestically and internationally, completing safety verification of the materials.

Furthermore, Jeonjin Biofarm has been diligently securing intellectual property rights, starting with domestic patent registration to exclusively use the active substances based on natural materials, followed by Norway and Chile overseas, and last year actively extending to the UK and Canada. Recently, it secured a patent for the core technology in Norway, which holds the largest market share in the sea lice treatment market. According to the company, this grants exclusive and exclusive rights for product commercialization along with global technological competitiveness.

A Jeonjin Biofarm official stated, “We are currently pursuing registration of the salmon parasite damage reduction agent not only as an animal drug but also as Feed Material. Through this two-track strategy, we will concentrate our capabilities on rapid commercialization and sales by promoting product registration.”

This content was produced with the assistance of AI translation services.